vtioВестник трансплантологии и искусственных органовRussian Journal of Transplantology and Artificial Organs1995-1191Academician V.I.Shumakov National Medical Research Center of Transplantology and Artificial Organs", Ministry of Health of the Russian Federation10.15825/1995-1191-2018-3-54-63vtio-912Research ArticleРегенеративная медицина и клеточные технологииRegenerative Medicine and Cell TechnologiesРоль мезенхимальных стволовых клеток костного мозга крысы в жизнеспособности островков Лангерганса при совместном культивировании с микрогетерогенным коллагенсодержащим гидрогелемInfluence of rat bone marrow mesenchymal stem cells to rat Langerhans islets viability during co-cultivation with microst ructured collagen‑containing hydrogelБарановаН. В.BaranovaN. V.

Адрес: 123182, Москва, ул. Щукинская, д. 1. Тел. (499) 190-42-66

Address: 1, Shchukinskaya st., Moscow, 123182, Russian Federation. Tel. (499) 190-42-66

barnats@yandex.ruКирсановаЛ. А.KirsanovaL. A.ГониковаЗ. З.GonikovaZ. Z.ПономареваА. С.PonomarevaA. S.СевастьяновВ. И.SevastianovV. I.ФГБУ «Национальный медицинский исследовательский центр трансплантологии и искусственных органов имени академика В.И. Шумакова» Минздрава РоссииРоссияV.I. Shumakov National Medical Research Center of Transplantology and Artificial Organs of the Ministry of Healthcare of the Russian FederationRussian Federation2018160920182035463Copyright © Баранова Н.В., Кирсанова Л.А., Гоникова З.З., Пономарева А.С., Севастьянов В.И., 20182018Баранова Н.В., Кирсанова Л.А., Гоникова З.З., Пономарева А.С., Севастьянов В.И.Baranova N.V., Kirsanova L.A., Gonikova Z.Z., Ponomareva A.S., Sevastianov V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.transpl.ru/vtio/article/view/912Введение

Введение. В качестве альтернативы трансплантации островков Лангерганса (ОЛ) предпринимаются попытки создания тканеинженерной конструкции поджелудочной железы  (ТИК ПЖ), состоящей из аллогенных ОЛ и биоактивного резорбируемого матрикса, создающего островкам микроокружение, сходное с нативным, и обеспечивающего островкам необходимые  условия для выживаемости и функциональной активности. Кроме того, сохранности  изолированных островков, по литературным данным, способствует сокультивирование с мезенхимальными стволовыми клетками (МСК).

Цель

Цель. Изучить влияние мезенхимальных стволовых клеток костного мозга (МСК КМ) крысы на  жизнеспособность изолированных ОЛ крысы при совместном культивировании с БМКГ.

Материалы и методы

Материалы и методы. Островки и МСК КМ выделяли, ориентируясь на классические  методики, с некоторыми модификациями. Эксперименты по сокультивированию проводили в  стандартных условиях. Жизнеспособность островков определяли методом иммунофлуоресцентного окрашивания.

Результаты

Результаты. При культивирование ОЛ с БМКГ и МСК КМ на третьи сутки наблюдались  деструктивные изменения островков, а на седьмые сутки отмечалось полное разрушение ОЛ. В то же время ОЛ, культивированные с БМКГ, сохраняли жизнеспособность в течение 14 суток инкубации.

Заключение

Заключение. Культивирование ОЛ с БМКГ и МСК КМ не способствовало длительному выживанию островков. Таким образом, позитивного влияния МСК КМ на  жизнеспособность панкреатических островков не наблюдалось.

Aim

Aim. To research the rat bone marrow mesenchymal stem cells (MSC BM) effect to the viability of isolated rat OL during cultivation with microstructured collagen-containing hydrogel (BMCH).

Materials and methods

Materials and methods. Rat islets and MSC BM were isolated according to  classical technique with some modifications. The experiments on the co- cultivation were carried out under standard conditions. Islet’s viability was  determined by immunofluorescence staining.

Results

Results. TheOL cultivation with BMCH and MSCBM resulted in destructive changes of isletson the third day, and complete destruction of OL was observed  on the seventh day. At the same time, OL cultured with BMCH remained viable for 14 days of incubation.

Conclusion

Conclusion. Cultivation of OL with BMCH and MSC BM did not contribute to the  long-term survival of the islets. Thus, there was no positive effect of MSC BM on the viability of pancreatic islets.

островки Лангергансамезенхимальные стволовые клетки костного мозгаколлагенсодержащий гелькультивированиеLangerhans isletsbone marrow mesenchymal stem cellscollagen-containing hydrogelcultivationReferencesShapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat. Rev. Endocrinol. 2016 Nov 11. DOI: 10.1038/nrendo.2016.178.Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat. Rev. Endocrinol. 2016 Nov 11. DOI: 10.1038/nrendo.2016.178.Karaoz E, Genc ZC, Demircan PC, Aksoy A, Duruksu G. Protection of rat pancreatic islet function and viability by coculture with rat bone marrow-derived mesenchymal stem cells. Cell Death Dis. 2010 Apr 22; 1: e36. DOI: 10.1038/cddis.2010.14.Karaoz E, Genc ZC, Demircan PC, Aksoy A, Duruksu G. Protection of rat pancreatic islet function and viability by coculture with rat bone marrow-derived mesenchymal stem cells. Cell Death Dis. 2010 Apr 22; 1: e36. DOI: 10.1038/cddis.2010.14.Scuteri A, Donzelli E, Rodriguez-Menendez V, Ravasi M, Monfrini M, Bonandrini B et al. A double mechanism for the mesenchymal stem cells’ positive effect on pancreatic islets. PLoS One. 2014 Jan 8; 9 (1): e84309. DOI: 10.1371/journal.pone.0084309.Scuteri A, Donzelli E, Rodriguez-Menendez V, Ravasi M, Monfrini M, Bonandrini B et al. A double mechanism for the mesenchymal stem cells’ positive effect on pancreatic islets. PLoS One. 2014 Jan 8; 9 (1): e84309. DOI: 10.1371/journal.pone.0084309.Matsumoto S. Islet cell transplantation for type 1 diabetes. J. Diabetes. 2010 Mar; 2 (1): 16–22. DOI: 10.1111/j.1753-0407.2009.00048.x.Matsumoto S. Islet cell transplantation for type 1 diabetes. J. Diabetes. 2010 Mar; 2 (1): 16–22. DOI: 10.1111/j.1753-0407.2009.00048.x.Ricordi C, Hering BJ, Shapiro AM. Clinical Islet Transplantation Consortium. Beta-cell transplantation for diabetes therapy. Lancet. 2008 Jul 5; 372 (9632): 27–28. DOI: 10.1016/S0140-6736(08)60984-8.Ricordi C, Hering BJ, Shapiro AM. Clinical Islet Transplantation Consortium. Beta-cell transplantation for diabetes therapy. Lancet. 2008 Jul 5; 372 (9632): 27–28. DOI: 10.1016/S0140-6736(08)60984-8.Llacua A, de Haan BJ, Sminc SA, de Vos P. Extracellular matrix components supporting human islet function in alginate-based immunoprotective microcapsules for treatment of diabetes. J. Biomed. Mater. Res. A. 2016 Jul; 104 (7): 1788–1796. DOI: 10.1002/jbm.a.35706.Llacua A, de Haan BJ, Sminc SA, de Vos P. Extracellular matrix components supporting human islet function in alginate-based immunoprotective microcapsules for treatment of diabetes. J. Biomed. Mater. Res. A. 2016 Jul; 104 (7): 1788–1796. DOI: 10.1002/jbm.a.35706.Berney T, Molano RD, Cattan P, Pileggi A, Vizzardelli C, Oliver R et al. Endotoxin- mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation. 2001 Jan 15; 71 (1): 125–132. PMID: 11211177.Berney T, Molano RD, Cattan P, Pileggi A, Vizzardelli C, Oliver R et al. Endotoxin- mediated delayed islet graft function is associated with increased intra-islet cytokine production and islet cell apoptosis. Transplantation. 2001 Jan 15; 71 (1): 125–132. PMID: 11211177.Zhang Y, Jalili RB, Warnock GL, Ao Z, Marzban L, Ghahary A. Three-dimensional scaffolds reduce islet amyloid and enhance function of cultured human islets. Am. J. Pathol. 2012 Oct; 181 (4): 1296–1305. DOI: 10.1016/j.ajpath.2012.06.032.Zhang Y, Jalili RB, Warnock GL, Ao Z, Marzban L, Ghahary A. Three-dimensional scaffolds reduce islet amyloid and enhance function of cultured human islets. Am. J. Pathol. 2012 Oct; 181 (4): 1296–1305. DOI: 10.1016/j.ajpath.2012.06.032.Jalili RB, Moeen Rezakhanlou A, Hosseini-Tabatabaei A, Ao Z, Warnock GL, Ghahary A. Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal. J. Cell Physiol. 2011 Jun; 226 (7): 1813–1819. DOI: 10.1002/jcp.22515.Jalili RB, Moeen Rezakhanlou A, Hosseini-Tabatabaei A, Ao Z, Warnock GL, Ghahary A. Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal. J. Cell Physiol. 2011 Jun; 226 (7): 1813–1819. DOI: 10.1002/jcp.22515.Stendahl JC, Kaufman DB, Stupp SI. Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. Cell Transplantation. 2009; 18 (1): 1– 12. PMID: 19476204.Stendahl JC, Kaufman DB, Stupp SI. Extracellular matrix in pancreatic islets: relevance to scaffold design and transplantation. Cell Transplantation. 2009; 18 (1): 1– 12. PMID: 19476204.Amer LD, Mahoney MJ, Bryant SJ. Tissue engineering approaches to cell-based type 1 diabetes therapy. Tissue engineering. 2014; Part B, 20 (5): 455–467. DOI: 10.1089/ten.TEB.2013.0462.Amer LD, Mahoney MJ, Bryant SJ. Tissue engineering approaches to cell-based type 1 diabetes therapy. Tissue engineering. 2014; Part B, 20 (5): 455–467. DOI: 10.1089/ten.TEB.2013.0462.Abualhassan N, Sapozhnikov L, Pawlick RL, Kahana M, Pepper AR, Bruni A et al. Lung- derived microscaffolds facilitate diabetes reversal after mouse and human intraperitoneal islet transplantation. PLoS One. 2016 May 26; 11 (5): e0156053. DOI: 10.1371/journal.pone.0156053.Abualhassan N, Sapozhnikov L, Pawlick RL, Kahana M, Pepper AR, Bruni A et al. Lung- derived microscaffolds facilitate diabetes reversal after mouse and human intraperitoneal islet transplantation. PLoS One. 2016 May 26; 11 (5): e0156053. DOI: 10.1371/journal.pone.0156053.Coronel M, Stabler C. Engineering a local microenvironment for pancreatic islet replacement. Curr. Opin. Biotechnol. 2013; 24: 900–908. DOI: 10.1016/j.copbio.2013.05.004.Coronel M, Stabler C. Engineering a local microenvironment for pancreatic islet replacement. Curr. Opin. Biotechnol. 2013; 24: 900–908. DOI: 10.1016/j.copbio.2013.05.004.Fisher SA, Tam RY, Shoichet MS. Tissuemimetics: engineered hydrogel matrices provide biomimetic environments for cell growth. Tissue Engineering. 2014; Part A, 20 (5,6): 895–898. DOI: 10.1089/ten.tea.2013.0765.Fisher SA, Tam RY, Shoichet MS. Tissuemimetics: engineered hydrogel matrices provide biomimetic environments for cell growth. Tissue Engineering. 2014; Part A, 20 (5,6): 895–898. DOI: 10.1089/ten.tea.2013.0765.Tziampazis E, Sambanis A. Tissue engineering of a bioartificial pancreas: modeling the cell environment and device function. Biotechnol. Prog. 1995 Mar-Apr; 11 (2): 115– 126. DOI: 10.1021/bp00032a001.Tziampazis E, Sambanis A. Tissue engineering of a bioartificial pancreas: modeling the cell environment and device function. Biotechnol. Prog. 1995 Mar-Apr; 11 (2): 115– 126. DOI: 10.1021/bp00032a001.Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009 Nov 27; 326 (5957): 1216–1219. DOI: 10.1126/science.1176009.Hynes RO. The extracellular matrix: not just pretty fibrils. Science. 2009 Nov 27; 326 (5957): 1216–1219. DOI: 10.1126/science.1176009.Riopel M, Wang R. Collagen matrix support of pancreatic islet survival and function. Front. Biosci. (Landmark Ed). 2014 Jan 1; 19: 77–90. PMID: 24389173.Riopel M, Wang R. Collagen matrix support of pancreatic islet survival and function. Front. Biosci. (Landmark Ed). 2014 Jan 1; 19: 77–90. PMID: 24389173.Ko JH, Kim YH, Jeong SH, Lee S, Park SN, Shim IK, Kim SC. Collagen esterification enhances the function and survival of pancreatic β-cells in 2D and 3D culture systems. Biochem. BIophys. Res. Commun. 2015 Aug 7; 483 (4): 1084–1090. DOI: 10.1016/j.bbrc.2015.06.062.Ko JH, Kim YH, Jeong SH, Lee S, Park SN, Shim IK, Kim SC. Collagen esterification enhances the function and survival of pancreatic β-cells in 2D and 3D culture systems. Biochem. BIophys. Res. Commun. 2015 Aug 7; 483 (4): 1084–1090. DOI: 10.1016/j.bbrc.2015.06.062.Salvay DM, Rives CB, Zhang X, Chen F, Kaufman DB, Lowe WL Jr, Shea LD. Extracellular matrix proteincoated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation. 2008 May 27; 85 (10): 1456–1464. DOI: 10.1097/TP.0b013e31816fc0ea.Salvay DM, Rives CB, Zhang X, Chen F, Kaufman DB, Lowe WL Jr, Shea LD. Extracellular matrix proteincoated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation. Transplantation. 2008 May 27; 85 (10): 1456–1464. DOI: 10.1097/TP.0b013e31816fc0ea.Hematti P, Kim J, Stein AP, Kaufman D. Potential role of mesenchymal stromal cells in pancreatic islet transplantation. Transplant. Rev. (Orlando) 27, 21, 2013. DOI: 10.1016/j.trre.2012.11.003.Hematti P, Kim J, Stein AP, Kaufman D. Potential role of mesenchymal stromal cells in pancreatic islet transplantation. Transplant. Rev. (Orlando) 27, 21, 2013. DOI: 10.1016/j.trre.2012.11.003.de Souza BM, Boucas AP, Oliveira FD, Reis KP, Ziegelmann P, Bauer AC, Crispim D. Effect of co-culture of mesenchymal stem/stromal cells with pancreatic islets on viability and function outcomes: a systematic review and meta-analysis. Islets. 2017 Mar 4; 9 (2): 30–42. DOI: 10.1080/19382014.2017.1286434.de Souza BM, Boucas AP, Oliveira FD, Reis KP, Ziegelmann P, Bauer AC, Crispim D. Effect of co-culture of mesenchymal stem/stromal cells with pancreatic islets on viability and function outcomes: a systematic review and meta-analysis. Islets. 2017 Mar 4; 9 (2): 30–42. DOI: 10.1080/19382014.2017.1286434.Jung EJ, Kim SC, Wee YM, Kim YH, Choi MY, Jeong SH et al. Bone marrow-derived mesenchymal stromal cells support rat pancreatic islet survival and insulin secretory function in vitro. Cytotherapy. 2011 Jan; 13 (1): 19–29. DOI: 10.3109/14653249.2010.518608.Jung EJ, Kim SC, Wee YM, Kim YH, Choi MY, Jeong SH et al. Bone marrow-derived mesenchymal stromal cells support rat pancreatic islet survival and insulin secretory function in vitro. Cytotherapy. 2011 Jan; 13 (1): 19–29. DOI: 10.3109/14653249.2010.518608.Hirabaru M, Kuroki T, Adachi T, Kitasato A, Ono S, Tanaka T et al. A metod for performing islet transplantation using tissue-engineered sheets of islets and mesenchymal stem cells. Tissue Eng Part C Methods. 2015 Dec; 21 (12): 1205–1215. DOI: 10.1089/ten.TEC.2015.0035.Hirabaru M, Kuroki T, Adachi T, Kitasato A, Ono S, Tanaka T et al. A metod for performing islet transplantation using tissue-engineered sheets of islets and mesenchymal stem cells. Tissue Eng Part C Methods. 2015 Dec; 21 (12): 1205–1215. DOI: 10.1089/ten.TEC.2015.0035.Figliuzzi M, Cornolti R, Perico N, Rota C, Morigi M, Remuzzi G et al. Bone marrow- derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant. Proc. 2009 Jun; 41 (5): 1797–1800. DOI: 10.1016/j.transproceed.2008.11.015.Figliuzzi M, Cornolti R, Perico N, Rota C, Morigi M, Remuzzi G et al. Bone marrow- derived mesenchymal stem cells improve islet graft function in diabetic rats. Transplant. Proc. 2009 Jun; 41 (5): 1797–1800. DOI: 10.1016/j.transproceed.2008.11.015.Sakata N, Chan NK, Chrisler J, Obenaus A, Hathout E. Bone marrow cell cotransplantation with islets improves their vascularization and function. Transplantation. 2010 Mar 27; 89 (6): 686–693. DOI: 10.1097/TP.0b013e3181cb3e8d.Sakata N, Chan NK, Chrisler J, Obenaus A, Hathout E. Bone marrow cell cotransplantation with islets improves their vascularization and function. Transplantation. 2010 Mar 27; 89 (6): 686–693. DOI: 10.1097/TP.0b013e3181cb3e8d.Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation. 2010 Jun 27; 89 (12): 1438–1445. PMID: 20568673.Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation. 2010 Jun 27; 89 (12): 1438–1445. PMID: 20568673.Перова НВ, Севастьянов ВИ. Биополимерный гетерогенный гидрогель Сферо®ГЕЛЬ – инъекционный биодеградируемый имплантат. Практическая медицина. 2014; 8 (84): 111–116. Perova NV, Sevastianov VI. Biopolimernyj geterogennyj gidrogel’ Sfero®GEL – inyektsionniy biodegradiruyemiy implantat. Prakticheskaya meditsina. 2014; 8 (84): 111–116.Перова НВ, Севастьянов ВИ. Биополимерный гетерогенный гидрогель Сферо®ГЕЛЬ – инъекционный биодеградируемый имплантат. Практическая медицина. 2014; 8 (84): 111–116. Perova NV, Sevastianov VI. Biopolimernyj geterogennyj gidrogel’ Sfero®GEL – inyektsionniy biodegradiruyemiy implantat. Prakticheskaya meditsina. 2014; 8 (84): 111–116.Баранова НВ, Кирсанова ЛА, Бубенцова ГН, Севастьянов ВИ. Микрогетерогенный коллагенсодержащий гидрогель как матрикс для изолированных островков Лангерганса поджелудочной железы крысы. Гены и клетки. Материалы III Национального конгресса по регенеративной медицине. 2017; XII (3): 38–39. Baranova NV, Kirsanova LA, Bubentsova GN, Sevastianov VI. Microstructured collagen-containing hydrogel as matrix for isolated islets of rat pancreas. Genes and Cells. Materials of the 3rd National congress on regenerative medicine. 2017; XII (3): 38–39.Баранова НВ, Кирсанова ЛА, Бубенцова ГН, Севастьянов ВИ. Микрогетерогенный коллагенсодержащий гидрогель как матрикс для изолированных островков Лангерганса поджелудочной железы крысы. Гены и клетки. Материалы III Национального конгресса по регенеративной медицине. 2017; XII (3): 38–39. Baranova NV, Kirsanova LA, Bubentsova GN, Sevastianov VI. Microstructured collagen-containing hydrogel as matrix for isolated islets of rat pancreas. Genes and Cells. Materials of the 3rd National congress on regenerative medicine. 2017; XII (3): 38–39.Севастьянов ВИ, Перова НВ, Немец ЕА и др. Примеры экспериментально- клинического применения биосовместимых материалов в регенеративной медицине. Биосовместимые материалы: учебное пособие. Под ред. В.И. Севастьянова, М.П. Кирпичникова. М.: МИА, 2011: 237–252. Sevastianov VI, Perova NV, Nemets EA i dr. Primery experimentalno-klinicheskogo primeneniya biosovmestimykh materialov v regenerativnoy meditsine. Biosovmestimiye materialy: uchebnoye posobiye. Pod red. V.I. Sevastianova, M.P. Kirpichnikova. M.: MIA, 2011: 237– 252.Севастьянов ВИ, Перова НВ, Немец ЕА и др. Примеры экспериментально- клинического применения биосовместимых материалов в регенеративной медицине. Биосовместимые материалы: учебное пособие. Под ред. В.И. Севастьянова, М.П. Кирпичникова. М.: МИА, 2011: 237–252. Sevastianov VI, Perova NV, Nemets EA i dr. Primery experimentalno-klinicheskogo primeneniya biosovmestimykh materialov v regenerativnoy meditsine. Biosovmestimiye materialy: uchebnoye posobiye. Pod red. V.I. Sevastianova, M.P. Kirpichnikova. M.: MIA, 2011: 237– 252.London NJ, Swift SM, Clayton HA. Isolation, culture and functional evaluation of islets of Langerhans. Diabetes Metab. 1998 Jun; 24 (3): 200–207. PMID: 9690051.London NJ, Swift SM, Clayton HA. Isolation, culture and functional evaluation of islets of Langerhans. Diabetes Metab. 1998 Jun; 24 (3): 200–207. PMID: 9690051.Kenmochi T, Asano T, Jingu K, Iwashita C, Miyauchi H, Takahashi S et al. Development of a fully automaited islet digestion system. Transplant. Proc. 2000 Mar; 32 (2): 341–343. PMID: 10715434.Kenmochi T, Asano T, Jingu K, Iwashita C, Miyauchi H, Takahashi S et al. Development of a fully automaited islet digestion system. Transplant. Proc. 2000 Mar; 32 (2): 341–343. PMID: 10715434.Pang X, Xue W, Feng X, Tian X, Teng Y, Ding X et al. Experimental studies on islets isolation, purification and function in rats. Int. J. Clin. Exp. Med. 2015 Nov 15; 8 (11): 20932–20938. PMID: 26885021.Pang X, Xue W, Feng X, Tian X, Teng Y, Ding X et al. Experimental studies on islets isolation, purification and function in rats. Int. J. Clin. Exp. Med. 2015 Nov 15; 8 (11): 20932–20938. PMID: 26885021.Готье СВ, Шагидулин МЮ, Онищенко НА, Крашенинников МЕ, Севастьянов ВИ. Способ и трансплантат для лечения печеночной недостаточности. Патент № 2010110063/14 (014141). 03.03.2011. Gautier SV, Shagidulin MY, Onishchenko NA, Krasheninnikov ME, Sevastiyanov VI. The method and graft for treating hepatic insufficiency. Patent number 2010110063/14 (014141). From 03.03.2011 (In Rus).Готье СВ, Шагидулин МЮ, Онищенко НА, Крашенинников МЕ, Севастьянов ВИ. Способ и трансплантат для лечения печеночной недостаточности. Патент № 2010110063/14 (014141). 03.03.2011. Gautier SV, Shagidulin MY, Onishchenko NA, Krasheninnikov ME, Sevastiyanov VI. The method and graft for treating hepatic insufficiency. Patent number 2010110063/14 (014141). From 03.03.2011 (In Rus).

The authors declare that there are no conflicts of interest present.